Amadeu Gavaldà

Dr. Amadeu Gavaldà

Pharmacology, Almirall (Spain), Barcelona, Catalonia, Spain
orcid
Pharmacology Director, Almirall

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1995 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
AAAntonio Armario
Antonio Armario
AGAmadeu Gavaldà
Amadeu Gavaldà
JMJoaquín Martí
Joaquín Martí


1 November 2009 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
AGAmadeu Gavaldà
Amadeu Gavaldà
MMMontserrat Miralpeix
Montserrat Miralpeix
IRIsrael Ramos
Israel Ramos
RORaquel Otal
Raquel Otal
CCCristina Carreño
Cristina Carreño
JBJorge Beleta
Jorge Beleta
Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease. Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M1–M5). [3H]Aclidinium dissociated slightly faster from M2 and M3 receptors than [3H]tiotropium but much more slowly than [3H]ipratropium. Its association rate for the M3 receptor was similar to [3H]ipratropium and 2.6 times faster than [3H]tiotropium. Residence half-life of [3H]aclidinium at the M2 receptor was shorter than at the M3 receptor, demonstrating kinetic selectivity for the M3 receptor. In isolated guinea pig trachea, aclidinium showed comparable potency to ipratropium and tiotropium, faster onset of action than tiotropium, and duration of action similar to tiotropium and significantly longer than ipratropium. Nebulized aclidinium inhibited bronchoconstriction induced by acetylcholine in guinea pigs in a concentration-dependent manner with an onset of action faster than tiotropium. Duration of action of aclidinium (t1/2 = 29 h) was much longer than ipratropium (8 h) but shorter than tiotropium (64 h). In dogs, aclidinium induced a smaller and more transient increase in heart rate than tiotropium at comparable supratherapeutic doses. Therefore, under these conditions, aclidinium showed a greater therapeutic index than tiotropium (4.2 versus 1.6). These results indicate that aclidinium is a potent muscarinic antagonist with a fast onset of action, a long duration of effect, and a favorable cardiovascular safety profile.

16 October 2009 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
LPLluis Pagès
Lluis Pagès
AGAmadeu Gavaldà
Amadeu Gavaldà
MLMartin D Lehner
Martin D Lehner
Background: Despite the sound preclinical database and some promising data from clinical trials, development of PDE4 inhibitors for the treatment of inflammatory or neurological diseases has been hampered by dose-limiting class-related side effects. Objective: In the past years, companies opted for different approaches to improve the therapeutic window of their compounds including topical administration of PDE4 inhibitors with the goal of minimizing systemic exposure. This change in strategy is reflected by the disclosure of novel and chemically diverse molecules that demonstrate the continued interest of pharmaceutical industry in developing PDE4 inhibitors. Conclusion: This review summarizes the clinical development of PDE4 inhibitors since 2005 and the associated patent literature with a focus on strategies applied to minimize systemic adverse effects. In sum, although a significant number of new drugs designed for improved tolerability entered clinical trials, so far none of them fulfilled expectation...

1 January 1994 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
OMOctavi Marti
Octavi Marti
AGAmadeu Gavaldà
Amadeu Gavaldà
FGFrancisca Gómez
Francisca Gómez
AAAntonio Armario
Antonio Armario
The ACTH response to CRF and the role of glucocorticoids on the pituitary-adrenal responsiveness to acute stressors after a period of chronic stress were assessed in Sprague-Dawley rats. After chronic immobilization (IMO) an enhanced ACTH response to CRF administration was observed. In another experiment, control and chronic IMO rats were adrenalectomized (ADX) or sham-adrenalectomized (SHAM) and 2 days later killed in resting conditions or after having been subjected to acute IMO or tail-shock for 30 min. Chronic IMO increased basal corticosterone but not adrenocorticotropin (ACTH) levels in SHAM rats. As expected, ADX increased ACTH levels in all conditions. In response to the novel acute stressor (shock), ACTH levels were drastically dependent on the presence of corticosterone: thus, whereas in SHAM rats chronic IMO reduced the ACTH response to shock, in ADX rats a clear enhancement of the ACTH response to shock was observed in chronic IMO rats. In order to demonstrate that, in our experimental conditions, chronic stress also induces down-regulation of glucocorticoid receptors in the hippocampus, an additional experiment was done: rats subjected chronically to IMO or administered 5 mg corticosterone (B) were adrenalectomized and killed 20 h later under basal conditions. Both chronic IMO and chronic B administration decreased glucocorticoid type II binding in the hippocampus. From these results, it is concluded that chronic IMO induces facilitation of the ACTH response to novel acute stressors which is uncovered after corticosterone removal.

1 September 2010 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
FMF. Mori
F. Mori
SPS. Pérez-Torres
S. Pérez-Torres
RCR. De Caro
R. De Caro
APA. Porzionato
A. Porzionato
Veronica MacchiVeronica Macchi
Veronica Macchi
GMG. Mengod
G. Mengod